

BREAST ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs	
				LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS			
S0221-Breast,Adj,N+,ACvAC+G/Pac q1v2	1 Y 1	AC+PEG-Gx6 then q2wk T+PEG-Gx6	3250	669	56	30	18	8	0	310	133
	2	AC+Gx15wks then q2wk T+PEG-Gx6		688	74	37	17	5	4		
	3	AC+PEG-Gx6 then weekly T x 12		686	50	23	13	7	0		
	4	AC+Gx15wks then weekly T x 12		638	59	27	17	5	0		
				2681	239	117	65	25	4		
S0230-Breast,Adj,Chemo +/- Goserelin	1 Y 1	Standard chemo	458	117	24	10	5	3	0	137	57
	2	Standard chemo + Goserelin		114	21	7	5	4	1		
				231	45	17	10	7	1		
S0500-Brst,Adv,CTC,mntain v chnge tx	1 Y 1	Initial screening blood draw	500	15	3	2	1	0	0	178	83
	2	< 5 CTC, Arm A (Low Risk)		200	67	40	10	3	1		
	3	>= 5 CTC, re-reg required		28	12	8	7	5	2		
	4	Maintain current therapy		154	48	25	8	1	0		
	5	Switch therapy		40	16	8	4	0	0		
				437	146	83	30	9	3		
	2 Y 6	Maintain current therapy	120	38	15	8	3	0	0	178	83
	7	Switch therapy		39	17	9	6	0	0		
				77	32	17	9	0	0		
S0622-Breast, Adv, 2 sched Dasatinib	1 Y 1	Dasatinib, 100 mg daily	80	39	14	6	4	4	2	135	57
	2	Dasatinib, 70 mg bid		37	11	4	2	1	0		
				76	25	10	6	5	2		
S0800-Brst,Neoadj nabPAC+/-Bev->AC+G	1 Y 1	Nab-PAC + BEV -> AC+PEG-G	200	5	5	5	4	2	0	160	56
	2	Nab-PAC -> AC + PEG-G		3	3	3	3	0	0		

BREAST ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs	
			TOTAL REGS.	LAST Month	LAST Month	LAST Month	LAST DAYS			LAST DAYS
S0800-Brst,Neoadj nabPAC+/-Bev->AC+G	1 Y 3 AC + PEG-G -> Nab-PAC	200	4	4	4	4	1	0	160	56
			12	12	12	11	3	0		
B39-Stg 0-2, whole vs partial RT	1 E Total Registrations		14	0	0	0	0	0	242	126
			14	0	0	0	0	0		
C40101-Breast, Adj, Node neg, AC vs T	1 E Total Registrations		733	22	9	2	0	0		
			733	22	9	2	0	0		
C40302-Endocrine +/- Inhibition	1 E Total Registrations		28	8	6	0	0	0	96	53
			28	8	6	0	0	0		
C40503-EndocrineTxCombo w/AntiVEGF Tx	1 E Total Registrations		7	7	7	3	0	0	77	40
			7	7	7	3	0	0		
C40601-NeoAdj, Her-2+, Pac+Trast or La	1 E Total Registrations		5	5	5	3	1	0	82	48
			5	5	5	3	1	0		
C70301-QOLEmployInformCareCost Analy	1 E Total Registrations		35	2	0	0	0	0	11	8
			35	2	0	0	0	0		
E1105-Adv, Trastuzumab +/- Bev	1 E Total Registrations		15	2	0	0	0	0	130	45

BREAST ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT.	# of CURR IRBs
				LAST Month	LAST Month	LAST Month	LAST DAYS	LAST DAYS		

			1700	444	218	115	46	5		
Z1071-Node+, chemo + LN dissect	1 E Total Registrations		15	15	13	5	3	1		
			15	15	13	5	3	1		

BREAST Open Studies with No Registrations

Study	Registration/Phase	OPENDT
C40603 Carb/Bev+Neoadj Pac, then AC/EC	1 Endorsed Study	21-May-10
MA.32 Metformn vs Placebo	1 Endorsed Study	08-Jul-10

2 rows selected.

no rows selected

BREAST SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E			SEGMENT	TOTAL REGS.		
	G N	ARM					
S0221-Breast,Adj,N+,ACvAC+G/Pac q1v2	1	Y	1	AC+PEG-Gx6 then q2wk T+PEG-Gx6	01: AC x 6	669	
			1	AC+PEG-Gx6 then q2wk T+PEG-Gx6	02: q 2wk Taxol + PEG-G	543	
			2	AC+Gx15wks then q2wk T+PEG-Gx6	01: AC+G	687	
			2	AC+Gx15wks then q2wk T+PEG-Gx6	02: q 2wk Taxol + PEG-G	530	
			3	AC+PEG-Gx6 then weekly T x 12	01: AC x 6	686	
			3	AC+PEG-Gx6 then weekly T x 12	02: weekly Taxol	575	
			4	AC+Gx15wks then weekly T x 12	01: AC+G	638	
			4	AC+Gx15wks then weekly T x 12	02: weekly Taxol	502	
	S0500-Brst,Adv,CTC,mntain v chnge tx	1	Y	1	Initial screening blood draw	01: Registration to 3 weeks	15
			1	Initial screening blood draw	02: 3-6 weeks	2	
			1	Initial screening blood draw	03: 6 weeks onward	2	
			2	< 5 CTC, Arm A (Low Risk)	01: Registration to 3 weeks	200	
			2	< 5 CTC, Arm A (Low Risk)	02: 3-6 weeks	11	
			2	< 5 CTC, Arm A (Low Risk)	03: 6 weeks onward	7	
			3	>= 5 CTC, re-reg required	01: Registration to 3 weeks	28	
			3	>= 5 CTC, re-reg required	02: 3-6 weeks	5	
			3	>= 5 CTC, re-reg required	03: 6 weeks onward	1	
			4	Maintain current therapy	01: Registration to 3 weeks	154	
			4	Maintain current therapy	02: 3-6 weeks	119	
			4	Maintain current therapy	03: 6 weeks onward	114	
			5	Switch therapy	01: Registration to 3 weeks	40	
			5	Switch therapy	02: 3-6 weeks	28	
			5	Switch therapy	03: 6 weeks onward	25	
		2	Y	6	Maintain current therapy	01: Registration to 3 weeks	38
				7	Switch therapy	01: Registration to 3 weeks	39
S0800-Brst,Neoadj nabPAC+/-Bev->AC+G	1	Y	1	Nab-PAC + BEV -> AC+PEG-G	01: Bevacizumab + nab-paclitaxel	5	
			2	Nab-PAC -> AC + PEG-G	01: Nab-paclitaxel	3	
			3	AC + PEG-G -> Nab-PAC	01: AC + PEG-G	4	

28 rows selected.